Navigation Links
New Drug May Help Fight Certain Advanced Lung Cancers
Date:6/3/2013

MONDAY, June 3 (HealthDay News) -- For patients struggling with a common and deadly form of lung cancer, adding the drug ganetespib to a standard chemotherapy drug may boost survival, new research suggests.

The finding centers on a class of medications known as heat shock protein 90 (Hsp90) inhibitors, and it's the first time in more than 10 years that researchers have uncovered a better way to treat this group of patients.

The findings were slated for presentation Monday in Chicago at the annual meeting of the American Society of Clinical Oncology.

"This is the first randomized study to demonstrate therapeutic benefit with a heat shock protein inhibitor in patients with cancer," study lead author Dr. Suresh Ramalingam, a professor of medical oncology at the Winship Cancer Institute of Emory University, in Atlanta, said in an ASCO news release.

The study focused on patients with a form of non-small cell lung cancer known as lung adenocarcinoma.

"We hope that the ongoing study will confirm our findings, as patients with this common form and stage of lung cancer urgently need more effective treatments," Ramalingam said.

The researchers said adenocarcinoma is the most common form of lung cancer. In the United States, it accounts for roughly 45 percent of the 170,000 non-small cell lung cancers diagnosed annually.

Ganetespib works by halting the function of newly established proteins that are involved in promoting the lung tumor's growth.

The new study was funded by drug maker Synta Pharmaceuticals and involved more than 250 patients, all of whom had tried standard treatments to no avail.

Half the patients were treated with the standard chemotherapy drug docetaxel, while the other half were given ganetespib in tandem with docetaxel.

Patients in the ganetespib group had longer average survival rates relative to those in the docetaxel-only group -- 9.8 months versus 7.4 months, respectively. Patients with advanced cancer that had been diagnosed at least six months prior to treatment saw a 67 percent boost in survival compared to similar patients who didn't get the new drug.

The researchers noted that prior trials on Hsp90 inhibitor drugs haven't panned out because side effects for patients were so dire. They said this is the first trial in which the drug has proven both safe and potentially effective.

Experts who weren't involved in the research were encouraged by the results.

"Ganetespib, in combination with docetaxel, shows promising early results in lung adenocarcinoma," Dr. Marjorie Zauderer, an ASCO spokeswoman and lung cancer expert, said in the news release. "We're hopeful about the outcome of an ongoing study, which could help more patients with this form of advanced lung cancer access this promising drug."

Dr. Len Horovitz, a pulmonary specialist at Lenox Hill Hospital in New York City, agreed.

"Finally there is a drug that can be offered to patients with advanced lung cancer, along with another drug," Horovitz said. "Ganetespib appears to increase overall survival independent of genetic markers. Since so many lung cancers are diagnosed at a late stage, this may help many patients."

Findings presented at medical meetings typically are considered preliminary until published in a peer-reviewed journal.

More information

For more on lung cancer, head to the U.S. National Cancer Institute.

-- Alan Mozes

SOURCES: June 3, 2013, news release, American Society of Clinical Oncology; Len Horovitz, M.D, pulmonary specialist, Lenox Hill Hospital, New York City


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. National Camp Series (NCS) Associate Chris Husby Joins Kicking For The Dream’s Effort to Fight Ovarian Cancer
2. Stress Kills (Literally), But It’s Not Too Late to Fight Back
3. Researchers discover new weapon in fight against cervical cancer
4. Immune system to fight brain tumors
5. Sport-Social for Autism Fights to Win Contest
6. Sailormen Inc. Popeyes Raises More than $670,000 to Help Fight Muscle Disease
7. Retired NFL Kicker and National Camp Series (NCS) Founder Michael Husted Joins Kicking For The Dream’s Effort to Fight Ovarian Cancer
8. Austin Sports Medicine Presents: Five Tips for Fighting Childhood Obesity
9. Common Supplement May Help Patients Fight Heart Failure
10. Modified Polio Virus May Help Fight Brain Tumors, Study Suggests
11. When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Drug May Help Fight Certain Advanced Lung Cancers
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... People across ... in Genome magazine’s Code Talker Award, an essay contest in which patients and their ... award to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... ... Haute Living, is proud to recognize Dr. Barry M. Weintraub as a prominent ... “the most beautiful women in the world, and the most handsome men, look ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, LLC ... by obtaining investment capital for emerging technology companies. SCP has delivered investment ... resulted in more than a million dollars of capital investment for five companies. ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Venture ... Golf Classic Tournament held on June 20th at the Woodmont Country Club at ... Luke’s Wings, an organization dedicated to helping service members that have been wounded in ...
(Date:6/24/2016)... ... June 24, 2016 , ... Advanced Plastic Surgery Institute ( ... as its official Medspa Sponsor. Dr. Josh Olson, a board-certified plastic surgeon, owns ... Dr. Olson says the decision to support the pageant in an official capacity ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016 The Academy of Managed Care Pharmacy ... that would allow biopharmaceutical companies to more easily share ... formulary and coverage decisions, a move that addresses the ... The recommendations address restrictions in the sharing ... drug label, a prohibition that hinders decision makers from ...
(Date:6/24/2016)... 2016 Research and Markets has announced ... Diagnostic Tests" report to their offering. ... The World Market for Companion Diagnostics covers ... Market analysis in the report includes the following: ... Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/24/2016)... , June 24, 2016 ... appointment of Dr. Edward Futcher to ... Director, effective June 23, 2016.Dr. Futcher was also ... and Governance Committees.  As a non-executive member of ... expertise and strategic counsel to VolitionRx in connection ...
Breaking Medicine Technology: